Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics' stock has experienced several notable events in the past six months. The company has received a range of analyst ratings, including "Moderate Buy", "Outperform", "Strong-Buy", "Buy", and "Overweight", with some firms increasing their price targets, while Wall Street Zen downgraded Kymera from a "hold" to a "sell" rating, and Weiss Ratings assigned a "Sell (D-)" rating. There have been significant insider sales, with CFO Bruce N. Jacobs, insider Jared Gollob, and Director Jeffrey W. Albers selling shares. Kymera reported its Q2 earnings on August 11, 2025, with an EPS of ($0.95), missing analyst estimates of ($0.83). Kymera presented new preclinical data for KT-579 at the American College of Rheumatology Annual Meeting in October 2025. In October 2024, Kymera announced FDA clearance of its IND application for KT-621. Citi placed Kymera Therapeutics on its 90-day catalyst watch list in anticipation of upcoming Phase 1b study results for KT-621.

As a clinical-stage biopharmaceutical company, Kymera Therapeutics' revenue streams are primarily driven by collaboration agreements and milestone payments, not typical seasonal fluctuations. The demand for its pipeline programs is driven by the progression of clinical trials and the unmet medical needs they aim to address.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins through targeted protein degradation (TPD). Its pipeline includes programs targeting IRAK4 (in Phase II clinical trials), STAT3, MDM2, KT-579 (an oral IRF5 degrader with Phase 1 trials anticipated in early 2026), and KT-621 (an oral STAT6 degrader expected to begin Phase 1 clinical trials in October 2024).

Kymera Therapeutics, Inc. is based in Watertown, Massachusetts. While its direct operations are concentrated in the US, it has partnerships with global pharmaceutical companies like Sanofi and Gilead, extending the potential reach of its therapies.

Kymera Therapeutics has been recognized as one of Boston's top workplaces for several years. The company generally holds a positive reputation among many financial analysts, with a consensus rating of "Moderate Buy" and numerous "Buy," "Outperform," and "Overweight" recommendations. However, its reputation has seen some mixed signals in the past year, with a "Sell" rating from Weiss Ratings and a downgrade from "hold" to "sell" by Wall Street Zen. Recent insider selling activity could also be perceived negatively by investors.

Major institutional owners of Kymera Therapeutics, Inc. include Price T Rowe Associates (9.59%), Baker Bros. Advisors (9.30%), Avoro Capital Advisors (9.17%), BVF (7.70%), and Wellington Management Group LLP (7.51%). Corporate insiders collectively own 16.01% of the company's stock.